News from wuxi apptec A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 31, 2023, 06:02 ET WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871...

Apr 24, 2023, 06:03 ET WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 20, 2023, 05:58 ET WuXi AppTec Reports Record Results in 2022

Revenue Up 71.8% Year-Over-Year to RMB39,355 Million Net Profit Attributable to Owners of the Company Up 72.9% Year-Over-Year to RMB8,814 Million...

Feb 15, 2023, 19:00 ET WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device...

Dec 20, 2022, 19:00 ET WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today...

Nov 29, 2022, 19:00 ET WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device...

Oct 26, 2022, 07:06 ET WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Sep 26, 2022, 08:00 ET WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high...

Sep 09, 2022, 08:00 ET WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and...

Aug 16, 2022, 13:47 ET WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new...

Aug 11, 2022, 21:09 ET WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one...

Jul 26, 2022, 05:30 ET WuXi AppTec Reports Record First-Half Results in 2022

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Jul 19, 2022, 05:57 ET WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation

WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today...

Jul 06, 2022, 20:00 ET WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its...

Jun 15, 2022, 20:00 ET WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage...

Apr 28, 2022, 05:09 ET WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR's Bioprocessing Technology Institute (BTI), announced a new...

Apr 25, 2022, 05:52 ET WuXi AppTec Reports Record First-Quarter In 2022

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Apr 07, 2022, 20:00 ET WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics

WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an...

Mar 23, 2022, 07:27 ET WuXi AppTec Reports Strong Revenue Growth in 2021

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...

Mar 07, 2022, 19:00 ET WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing...

Feb 10, 2022, 21:00 ET WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, ...

Dec 15, 2021, 19:00 ET Statement by WuXi AppTec Regarding Recent Market Fluctuation

Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the...

Dec 08, 2021, 19:00 ET WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced...

Nov 15, 2021, 07:00 ET WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing...

Oct 29, 2021, 05:41 ET WuXi AppTec Reports Strong Third-Quarter 2021 Results

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable...